中恒集团：控股子公司产品取得注册证

Core Viewpoint - Zhongheng Group has received approval for two new drugs, which may enhance its market position and revenue potential in the pharmaceutical sector [1] Company Summary - Zhongheng Group's subsidiary, Chongqing Laimei Pharmaceutical Co., Ltd., has obtained drug registration certificates for Nicardipine Tablets and Ketorolac Tromethamine Injection from the National Medical Products Administration [1] - As of the latest report, Zhongheng Group's market capitalization stands at 9.3 billion yuan [1] Industry Summary - For the fiscal year 2024, Zhongheng Group's revenue composition is as follows: 76.26% from pharmaceutical manufacturing, 13.84% from other businesses, and 9.9% from food [1]